Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.

Larsen, R; Ryder, L P; Svejgaard, A; Gniadecki, R

Larsen, R; Ryder, L P; Svejgaard, A; Gniadecki, R.

Affiliation

Larsen R; Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark. runel@dadlnet.dk

Clin Exp Immunol ; 149(1): 23-30, 2007 Jul.

Article in En | MEDLINE | ID: mdl-17403057

Subject(s)

Dermatologic Agents/pharmacology; Psoriasis/immunology; Recombinant Fusion Proteins/pharmacology; T-Lymphocyte Subsets/drug effects; Adult; Aged; Alefacept; CD2 Antigens/blood; CD4-Positive T-Lymphocytes/drug effects; Cyclosporine/pharmacology; Cyclosporine/therapeutic use; Dermatologic Agents/therapeutic use; Drug Administration Schedule; Flow Cytometry; Humans; Immunologic Memory; Immunosuppressive Agents/pharmacology; Immunosuppressive Agents/therapeutic use; Killer Cells, Natural/drug effects; Lymphocyte Count; Methotrexate/pharmacology; Methotrexate/therapeutic use; Middle Aged; Psoriasis/drug therapy; Recombinant Fusion Proteins/therapeutic use; Severity of Illness Index; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Recombinant Fusion Proteins / T-Lymphocyte Subsets / Dermatologic Agents Type of study: Risk_factors_studies Limits: Adult / Aged / Humans / Middle aged Language: En Journal: Clin Exp Immunol Year: 2007 Document type: Article Affiliation country: Denmark Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google